Monte Rosa Therapeutics Inc
Company Profile
Business description
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
Contact
321 Harrison Avenue
Suite 900
BostonMA02118
USAT: +1 617 949-2643
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
103
Stocks News & Analysis
stocks
10 of the cheapest global companies with wide moats
stocks
Bookworm: Buy and hold inspiration from an unlikely source
stocks
3 ASX shares to avoid
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,082.10 | 68.80 | 0.86% |
CAC 40 | 8,052.36 | 24.08 | 0.30% |
DAX 40 | 23,031.39 | 44.57 | 0.19% |
Dow JONES (US) | 41,488.19 | 674.62 | 1.65% |
FTSE 100 | 8,655.43 | 23.10 | 0.27% |
HKSE | 24,145.57 | 185.59 | 0.77% |
NASDAQ | 17,754.09 | 105.64 | 0.60% |
Nikkei 225 | 37,396.52 | 343.42 | 0.93% |
NZX 50 Index | 12,166.14 | 100.11 | -0.82% |
S&P 500 | 5,638.94 | 117.42 | 2.13% |
S&P/ASX 200 | 7,854.10 | 64.40 | 0.83% |
SSE Composite Index | 3,426.13 | 6.57 | 0.19% |